Correlation of Serum IL-2 and IFN-γ Levels with Clinical Prognosis of Nasopharyngeal Carcinoma Patients and Analysis of Risk Factors
Serum cytokine levels and prognosis in nasopharyngeal carcinoma
Abstract
Background: To explore the correlation of serum levels of interleukin-2 (IL-2) and interferon-γ (IFN-γ) with the clinical prognosis of patients with nasopharyngeal carcinoma (NPC) and analyze the risk factors.
Methods: The clinical data of 195 NPC patients admitted to our hospital from October 2020 to October 2022 were selected for retrospective study. The patients who obtained 0 point were in good prognosis group (group g), while those who obtained 1-2 points were in poor prognosis group (group p) based on Glasgow score. The levels of serum IL-2 and IFN-γ were compared between the two groups, and the clinical values of serum IL-2 and IFN-γ in the prognosis of patients were analyzed. The clinical parameters of the patients were collected, and the risk factors affecting the prognosis of NPC were analyzed by univariate and multivariate Logistic regression.
Results: Among 195 patients, 125 were in the group g and 70 were in the group p. The levels of IL-2 and IFN-γ in the group g were higher than the group p (P<0.05). The predictive AUC (95%CI) of IL-2 and IFN-γ were 0.846 (0.791-0.902) and 0.851 (0.797-0.904), respectively (P<0.05). Logistic regression analysis showed that age, tumor diameter, clinical stages and degree of differentiation were risk factors for the prognosis of NPC patients.
Conclusion: The levels of serum IL-2 and IFN-γ are closely related to the prognosis of NPC patients, and have certain value in evaluating the prognosis of patients. The age, tumor diameter, tumor staging and degree of tumor differentiation are all risk factors affecting the prognosis of patients, which can provide a reference for the selection of clinical treatment methods and evaluation of prognosis.
References
1. Zhang Z, Du J, Xu Q, Xing C, Li Y, Zhou S, et al. Adiponectin Suppresses Metastasis of Nasopharyngeal Carcinoma through Blocking the Activation of NF-kappaB and STAT3 Signaling. Int J Mol Sci 2022; 23(21):
2. Fang Z, Huang H, Wang L, Lin Z. Identification of the alpha linolenic acid metabolism-related signature associated with prognosis and the immune microenvironment in nasopharyngeal carcinoma. Front Endocrinol 2022; 13: 968984.
3. Yuan X, Yang H, Zeng F, Zhou S, Wu S, Yuan Y, et al. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA. Bmc Cancer 2022; 22(1): 858.
4. Mardhiyah I, Ardiyan YN, Aliyah SH, Sitepu EC, Herdini C, Dwianingsih EK, et al. Necrosis Factor-alpha (TNF-alpha) and the Presence of Macrophage M2 and T Regulatory Cells in Nasopharyngeal Carcinoma. Asian Pac J Cancer Prev 2021; 22(8): 2363-70.
5. Tsai MH, Chiou SH, Chow KC. Effect of platelet activating factor and butyrate on the expression of interleukin-2 receptor alpha in nasopharyngeal carcinoma cells. Int J Oncol 2001; 19(5): 1049-55.
6. Hsu MM, Chen YJ, Chang YL, Ko JY, Sheen TS. Soluble interleukin-2 receptor as a clinical parameter for nasopharyngeal carcinoma. Asian Pac J Allergy 1995; 13(1): 1-4.
7. Guo L, Chen Y, Wang J, Chen C. Down-regulation of UL16-binding protein 3 mediated by interferon-gamma impairs immune killing in nasopharyngeal carcinoma. Am J Transl Res 2020; 12(10): 6509-23.
8. Liou AK, Soon G, Tan L, Peng Y, Cher BM, Goh BC, et al. Elevated IL18 levels in Nasopharyngeal carcinoma induced PD-1 expression on NK cells in TILS leading to poor prognosis. Oral Oncol 2020; 104: 104616.
9. Al-Kholy AF, Abdullah OA, Abadier MZ, Hassaan MM, Shindy MF, Nor ED, et al. Pre-treatment serum inflammatory cytokines as survival predictors of patients with nasopharyngeal carcinoma receiving chemoradiotherapy. Mol Clin Oncol 2016; 5(6): 811-6.
10. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama-J Am Med Assoc 2013; 310(20): 2191-4.
11. Tu X, Ren J, Zhao Y. Prognostic value of prognostic nutritional index in nasopharyngeal carcinoma: A meta-analysis containing 4511 patients. Oral Oncol 2020; 110: 104991.
12. Zhang B, Miao T, Shen X, Bao L, Zhang C, Yan C, et al. EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization. Cell Death Dis 2020; 11(9): 742.
13. He WZ, Jiang C, Liu LL, Yin CX, Rong YM, Hu WM, et al. Association of body composition with survival and inflammatory responses in patients with non-metastatic nasopharyngeal cancer. Oral Oncol 2020; 108: 104771.
14. Wu L, Chung YL. Tumor-Infiltrating T Cell Receptor-Beta Repertoires are Linked to the Risk of Late Chemoradiation-Induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma. Int J Radiat Oncol 2019; 104(1): 165-76.
15. Jin YB, Zhang GY, Lin KR, Chen XP, Cui JH, Wang YJ, et al. Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT). Plos One 2017; 12(2): e172264.
16. Jin S, Li R, Chen MY, Yu C, Tang LQ, Liu YM, et al. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Res 2020; 30(11): 950-65.
17. Zhong L, Li C, Ren Y, Wu D. Prognostic value of (18)F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma. Oncol Lett 2017; 14(4): 5004-12.
18. Wang HM, Lin TL, Kuo YC, Li HP, Chang KP, Lin CY, et al. Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. Oncotarget 2016; 7(33): 53217-29.
19. Wang Y, Zhang W, Wu X, Luo X, Li S, Zhu G, et al. Cerebral Structural Abnormalities and Their Associations With Peripheral Cytokine Levels in a Group of Untreated Patients With Nasopharyngeal Carcinoma. Front Oncol 2021; 11: 740033.
20. Sun W, Zhang L, Luo M, Hu G, Mei Q, Liu D, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck-J Sci Spec 2016; 38 Suppl 1: E1332-40.
21. Hsiao SH, Lee MS, Lin HY, Su YC, Ho HC, Hwang JH, et al. Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma. Acta Oto-Laryngol 2009; 129(12): 1519-23.
22. Pisano G, Roy A, Ahmed AM, Kumar B, Chikoti L, Chandran B. Interferon-gamma-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency. Virol J 2017; 14(1): 221.
23. Hao K, Yan Z, Shuang Y, Sun J, Tao S, Fu W, et al. Association between interferon gamma 13-CA-repeats polymorphism and metastasis of nasopharyngeal carcinoma in a population of Northern China. Int J Clin Exp Patho 2015; 8(6): 7409-14.
24. He YW, Wang HS, Zeng J, Fang X, Chen HY, Du J, et al. Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells. Life Sci 2013; 93(15): 509-15.
25. Lin YH, Huang TL, Chien CY, Chen HC, Hsu HC, Huang EY, et al. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy. Radiat Oncol 2018; 13(1): 45.
Copyright (c) 2023 Siquan Guo, Feng Qin, Jiang Wang, Yongqing Ding, Jianqiang You, Changjiang Chao
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.